Triple Negative Breast Cancer and Celecoxib. Pilot Study

NCT07104266 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Celecoxib (Celebrex)
DRUG: Placebo

Sponsor

Université de Sherbrooke